Comparison of Spirofy™ and Vitalograph Alpha Touch™ Spirometers
Study Overview
Spirofy is India’s first portable, pneumotach flow-sensor-based digital spirometer designed for diagnosing asthma and COPD. This study compared Spirofy’s performance with the Vitalograph Alpha Touch spirometer in measuring lung capacities of healthy individuals, asthmatics, and COPD patients. The study also assessed the consistency between two Spirofy devices.
Key Findings
Ninety subjects participated in the study. The mean forced vital capacity (FVC) values obtained from Spirofy 1, Spirofy 2, and Vitalograph Alpha Touch were 2.60 L, 2.64 L, and 2.67 L, respectively. The mean forced expiratory volume in the first second (FEV1) values obtained from the devices were 1.87 L, 1.88 L, and 1.93 L, respectively. The Spirofy device demonstrated good sensitivity (97%), specificity (90%), and overall accuracy (93.3%) in detecting an FEV1/FVC ratio < 0.7 compared to the Vitalograph Alpha Touch spirometer. No variability was observed between the two Spirofy devices.
Conclusion
Spirofy is a portable, user-friendly device that is as accurate as the standard Vitalograph Alpha Touch spirometer for diagnosing COPD and asthma.
Practical Solutions and Value
Clinical trials are essential for developing safe treatments, and our AI-driven platform, DocSym, consolidates clinical protocols and research into a single, easily accessible knowledge base for clinicians. Our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and expanding digital services to improve patient care and outcomes.
By leveraging AI, clinics can enhance workflows, reduce paper routines, and improve patient outcomes. Learn more about how we can help at aidevmd.com.